Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults

Monseu, M.; Dubois, Séverine; Boursier, Jérôme; Aubé, Christophe; Gagnadoux, Frédéric; Lefthériotis, Georges; Ducluzeau, Pierre-Henri

doi:10.1016/j.diabet.2016.02.004

Cited by 22 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is also study reported that there is a link between TNFRSF9/CD137 and NAFLD in mice, showing that deficiency of TNFRSF9/CD137 prevents the mice from the development of NAFLD (Kim et al , 2011b). Hepatic cells are known to be able to produce OPG, and the plasma level of OPG has been shown to be positively correlated with liver fat content in dysmetabolic adults (Monseu et al , ). The plasma level of CCL23 has also been associated with plasma oxidative low‐density lipoprotein (Kim et al , 2011a), which could affect the redox balance in hepatic cells, and the latter has been linked to hepatic steatosis in recent studies (Walenbergh et al , ).…”

Section: Resultsmentioning

confidence: 99%

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease

Zhang

Arif

Tebani

et al. 2020

Molecular Systems Biology

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) continues to increase dramatically, and there is no approved medication for its treatment. Recently, we predicted the underlying molecular mechanisms involved in the progression of NAFLD using network analysis and identified metabolic cofactors that might be beneficial as supplements to decrease human liver fat. Here, we first assessed the tolerability of the combined metabolic cofactors including L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine by performing a 7-day rat toxicology study. Second, we performed a human calibration study by supplementing combined metabolic cofactors and a control study to study the kinetics of these metabolites in the plasma of healthy subjects with and without supplementation. We measured clinical parameters and observed no immediate side effects. Next, we generated plasma metabolomics and inflammatory protein markers data to reveal the acute changes associated with the supplementation of the metabolic cofactors. We also integrated metabolomics data using personalized genome-scale metabolic modeling and observed that such supplementation significantly affects the global human lipid, amino acid, and antioxidant metabolism. Finally, we predicted blood concentrations of these compounds during daily long-term supplementation by generating an ordinary differential equation model and liver concentrations of serine by generating a pharmacokinetic model and finally adjusted the doses of individual metabolic cofactors for future human clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease

Zhang

Arif

Tebani

et al. 2020

Molecular Systems Biology

View full text Add to dashboard Cite

show abstract

“…Our results are consistent with those of Erol et al [14] in 174 children and adolescents; they failed to find an association of osteoprotegerin with HOMA-IR. Though there is a relationship between osteoprotegerin and liver fat in adults [11] which constitutes a risk factor for insulin resistance, the relevance of this bone marker for glucose metabolism, particularly in children and adolescents, remains unclear and is probably minimal.…”

Section: Discussionmentioning

confidence: 99%

“…In a study on 70 children and adolescents, osteoprotegerin did not correlate significantly with age, height, or BMI [10]. In several studies, serum osteoprotegerin has been found to increase with liver fat content [11], and osteoprotegerin levels are higher in adults with diabetes or prediabetes than in those with normal glucose tolerance [12]. In obese adolescents, there was a positive correlation of osteoprotegerin with several parameters of insulin resistance (i.e., fasting serum insulin and HOMA-IR) [13], which was, however, not confirmed by another study including children and adolescents [14].…”

Section: Introductionmentioning

confidence: 99%

The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity

et al. 2019

View full text Add to dashboard Cite

Background/Aims: Sclerostin, osteoprotegerin, and bone-specific alkaline phosphatase (B-ALP), which are primarily related to bone metabolism, have been linked with insulin resistance in adults. We aimed to evaluate the association of these markers with growth, obesity, and parameters of insulin resistance in lean and obese children and adolescents. Methods: We measured sclerostin, osteoprotegerin, and B-ALP in fasting and oral glucose tolerance test (oGTT) serum samples from 1,325 children and adolescents, and during 24-h profiles and after exercise and glucose exposure in young adults. Results: In addition to the positive relationship with height standard deviation scores (SDS), sclerostin (r = 0.035, p < 0.001) and B-ALP (r = 0.06, p = 0.028) increased, whereas osteoprotegerin (r = –0.098, p < 0.001) decreased with BMI SDS. Furthermore, B-ALP correlated with fasting- and oGTT-derived markers of glucose and insulin metabolism suggestive of insulin resistance. To evaluate potential confounding diurnal variation of bone markers, we performed 24-h profiles. B-ALP and osteoprotegerin had lower night-time levels. Exercise acutely and transiently increased B-ALP and osteoprotegerin levels, but glucose ingestion had no effect. Conclusions: Besides their association with growth, sclerostin and osteoprotegerin levels are altered in childhood obesity. Particularly B-ALP was related to insulin resistance indices. Our findings accent the link between bone, growth, and insulin resistance.

show abstract

“… 17 Similarly in another study OPG levels were positively associated with fat content of the liver and researchers were of the view that OPG might play a significant role in development of various liver diseases. 18 …”

Section: Discussionmentioning

confidence: 99%

Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker

Tariq

Hussain

et al. 2020

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To determine the association of serum osteoprotegerin (OPG) with the severity of chronic liver disease in female patients. Methods: This case-control study was conducted in Madina Teaching Hospital from 2019-2020.An institutional review board of University Medical and Dental College, The University of Faisalabad gave the approval to conduct the study. Only female patients of age group 40 to 60 years having CLD were included in this study. Total 80 participants were enrolled after fulfilling the inclusion and exclusion criteria. Serum OPG levels were measured by enzyme linked immunosorbant assay (ELISA) supplied by ELAB Sciences, USA. The severity of disease was assessed by Child-Pugh classification. Results: OPG levels were significantly different between the three Child-Pugh classes. OPG levels were significantly high in class C indicating increased level of this cytokine in CLD as compared to class A (p = <0.05). There was a positive association of OPG with splenomegaly (OR = 2.10, p = <0.001), hepatomegaly (OR = 4.41, (p = < 0.05), skin pigmentation (OR = 2.06, p = <0.05), malena (OR = 1.87, p = <0.05) and prolonged bleeding (OR = 1.86, p = <0.05). Conclusion: The levels of serum Osteoprotegerin is increased in severe form of chronic liver disease (Class C) of Child-Pughs classification as compared to mild (Class A) and moderate (Class B) forms of Child-Pughs classification. doi: https://doi.org/10.12669/pjms.36.6.2678 How to cite this:Tariq S, Tariq S, Hussain S, Baig M. Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker. Pak J Med Sci. 2020;36(6):---------. doi: https://doi.org/10.12669/pjms.36.6.2678 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults

Cited by 22 publications

References 16 publications

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease

The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity

Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker

Contact Info

Product

Resources

About